349 related articles for article (PubMed ID: 27178984)
1. Effect of First-Line Treatment on Myeloid-Derived Suppressor Cells' Subpopulations in the Peripheral Blood of Patients with Non-Small Cell Lung Cancer.
Koinis F; Vetsika EK; Aggouraki D; Skalidaki E; Koutoulaki A; Gkioulmpasani M; Georgoulias V; Kotsakis A
J Thorac Oncol; 2016 Aug; 11(8):1263-1272. PubMed ID: 27178984
[TBL] [Abstract][Full Text] [Related]
2. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma.
Feng PH; Chen KY; Huang YC; Luo CS; Wu SM; Chen TT; Lee CN; Yeh CT; Chuang HC; Han CL; Lin CF; Lee WH; Kuo CH; Lee KY
J Thorac Oncol; 2018 Jul; 13(7):958-967. PubMed ID: 29684573
[TBL] [Abstract][Full Text] [Related]
4. Thymosin alpha-1 blocks the accumulation of myeloid suppressor cells in NSCLC by inhibiting VEGF production.
Yang Z; Guo J; Cui K; Du Y; Zhao H; Zhu L; Weng L; Tang W; Guo J; Zhang T; Shi X; Zong H; Jin S; Ma W
Biomed Pharmacother; 2020 Nov; 131():110740. PubMed ID: 32942159
[TBL] [Abstract][Full Text] [Related]
5. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
Liu CY; Wang YM; Wang CL; Feng PH; Ko HW; Liu YH; Wu YC; Chu Y; Chung FT; Kuo CH; Lee KY; Lin SM; Lin HC; Wang CH; Yu CT; Kuo HP
J Cancer Res Clin Oncol; 2010 Jan; 136(1):35-45. PubMed ID: 19572148
[TBL] [Abstract][Full Text] [Related]
6. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer.
Feng PH; Lee KY; Chang YL; Chan YF; Kuo LW; Lin TY; Chung FT; Kuo CS; Yu CT; Lin SM; Wang CH; Chou CL; Huang CD; Kuo HP
Am J Respir Crit Care Med; 2012 Nov; 186(10):1025-36. PubMed ID: 22955317
[TBL] [Abstract][Full Text] [Related]
7. Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer.
Yamauchi Y; Safi S; Blattner C; Rathinasamy A; Umansky L; Juenger S; Warth A; Eichhorn M; Muley T; Herth FJF; Dienemann H; Platten M; Beckhove P; Utikal J; Hoffmann H; Umansky V
Am J Respir Crit Care Med; 2018 Sep; 198(6):777-787. PubMed ID: 29617574
[TBL] [Abstract][Full Text] [Related]
8. LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer.
Zhao T; Liu S; Hanna NH; Jalal S; Ding X; Wan J; Yan C; Du H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914206
[TBL] [Abstract][Full Text] [Related]
9. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.
Dubinski D; Wölfer J; Hasselblatt M; Schneider-Hohendorf T; Bogdahn U; Stummer W; Wiendl H; Grauer OM
Neuro Oncol; 2016 Jun; 18(6):807-18. PubMed ID: 26578623
[TBL] [Abstract][Full Text] [Related]
10. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
[TBL] [Abstract][Full Text] [Related]
11. [Circulating Myeloid Suppressor Cells and Their Role in Tumour Immunology].
Pilatova K; Budinská E; Bensciková B; Nenutil R; Šefr R; Fedorová L; Hanáková B; Brychtová V; Zdražilová Dubská L
Klin Onkol; 2017; 30(Supplementum1):166-169. PubMed ID: 28471197
[TBL] [Abstract][Full Text] [Related]
12. MDSC subtypes and CD39 expression on CD8
Koh J; Kim Y; Lee KY; Hur JY; Kim MS; Kim B; Cho HJ; Lee YC; Bae YH; Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Eur J Immunol; 2020 Nov; 50(11):1810-1819. PubMed ID: 32510574
[TBL] [Abstract][Full Text] [Related]
13. Yeast-Derived Particulate β-Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation to APC in Cancer.
Albeituni SH; Ding C; Liu M; Hu X; Luo F; Kloecker G; Bousamra M; Zhang HG; Yan J
J Immunol; 2016 Mar; 196(5):2167-80. PubMed ID: 26810222
[TBL] [Abstract][Full Text] [Related]
14. Circulating CD15
Tian X; Wang T; Zheng Q; Tao Y; Dai L; Shen H
Int J Clin Pract; 2021 Aug; 75(8):e14317. PubMed ID: 33960078
[TBL] [Abstract][Full Text] [Related]
15. Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer.
Youn JI; Park SM; Park S; Kim G; Lee HJ; Son J; Hong MH; Ghaderpour A; Baik B; Islam J; Choi JW; Lee EY; Kim HR; Seo SU; Paik S; Yoon HI; Jung I; Xin CF; Jin HT; Cho BC; Seong SY; Ha SJ; Kim HR
Sci Rep; 2020 Jun; 10(1):9050. PubMed ID: 32493990
[TBL] [Abstract][Full Text] [Related]
16. Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue.
Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Petersen-Baltussen HM; ter Laan M; Wesseling P; Adema GJ
J Neuropathol Exp Neurol; 2015 May; 74(5):390-400. PubMed ID: 25853692
[TBL] [Abstract][Full Text] [Related]
17. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
[TBL] [Abstract][Full Text] [Related]
18. The significant increase and dynamic changes of the myeloid-derived suppressor cells percentage with chemotherapy in advanced NSCLC patients.
Wang S; Fu Y; Ma K; Liu C; Jiao X; Du W; Zhang H; Wu X
Clin Transl Oncol; 2014 Jul; 16(7):616-22. PubMed ID: 24193866
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients.
Adamo A; Frusteri C; Pilotto S; Caligola S; Belluomini L; Poffe O; Giacobazzi L; Dusi S; Musiu C; Hu Y; Wang T; Rizzini D; Vella A; Canè S; Sartori G; Insolda J; Sposito M; Incani UC; Carbone C; Piro G; Pettinella F; Qi F; Wang D; Sartoris S; De Sanctis F; Scapini P; Dusi S; Cassatella MA; Bria E; Milella M; Bronte V; Ugel S
Oncoimmunology; 2023; 12(1):2253644. PubMed ID: 37720688
[TBL] [Abstract][Full Text] [Related]
20. Circulating Levels of Monocytic Myeloid-Derived Suppressor Cells (M-MDSC) and CXCL-8 in Non-Small Cell Lung Cancer (NSCLC).
Zadian SS; Adcock IM; Salimi B; Mortaz E
Tanaffos; 2021 Jan; 20(1):15-21. PubMed ID: 34394365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
